Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Hospitals & Diagnostics
    • Fortis board members...

    Fortis board members deny allegations made by 2 institutional shareholders

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-05-10T16:48:48+05:30  |  Updated On 10 May 2018 4:48 PM IST
    Fortis board members deny allegations made by 2 institutional shareholders



    New Delhi: Fortis Healthcare's four directors, whose removal has been sought by two institutional shareholders, have denied allegations that they failed to maintain corporate governance and fairly represent interests of all shareholders.

    In a joint representation to shareholders, Brian W Tempest, Harpal Singh, Sabina Vaisoha and Tejinder S Shergill said the board had decided to consider only binding bids for Fortis, considering the immediate financing needs of the company.

    National Westminster Bank Plc as trustee of Jupiter India Fund and East Bridge Capital Master Fund, which together hold 12.04 percent stake in Fortis Healthcare, have demanded that the matter of removal of these directors from the company's board be taken up at the company's EGM on May 22.

    In their letter to the shareholders, the directors said the board decided to consider only binding bids as "the non-binding bids involve considerable uncertainty and merely running a due diligence process does not guarantee a binding bid, which the board had wanted in the best interest of the company".

    They added: "Given that there are four binding offers for consideration as on date and considering the need for a certain and quick solution for the company, it was considered prudent that only binding bids should be considered."

    Manipal-TPG, Munjals-Burmans, IHH Healthcare and KKR-backed Radiant Life Care have given binding offers to acquire Fortis. The company's board will decide the winning bid on May 10.

    They directors said that in the last 18 months, Fortis has been trying to close a possible transaction and has seen interest from both financial and strategic players.

    Stating that significant amount of time and effort of the management has been spent with the potential investors, they said the board "wished to end this seemingly unending process in the best interest of the company and therefore decided to evaluate only the binding bids..."

    The four board members further said their decision was also supported by the new additional board members, who were suggested by the two institutional shareholders.

    Refuting allegations of not exercising their fiduciary duties, the board members said after media reports came out, and before the formal institution of an investigation by SEBI and other regulatory bodies, the audit committee of the board, initiated an independent enquiry by Luthra & Luthra Law Offices.

    "Taking the ground of governance and our fiduciary duty, we directed the management to accord all assistance to the investigating agencies, and to make sure that the allegations are thoroughly examined in order to facilitate a complete impartial investigation," they said in their letter.

    Calling for a continuity of the members, they said, "We believe that the current Board due to its association with the company over a period of time is completely capable of taking the company out of its current issues and is also familiar with the workings of the company and the skill sets of the management."

    A complete change of the entire board at this time will certainly add more turbulence and ambiguity for Fortis as well as the management, they claimed while asking the shareholders to take an informed decision while voting on the requisition by the two shareholders.

    Stating that appointment of Lt Gen Shergill as an independent director for five years with effect from February 12, 2018 has already been approved the shareholders via a postal ballot, the directors said, "This to us also conveys that the majority of the shareholders are supportive of the current Board and its decision."

    Read Also: TPG-Backed Manipal Revises Bid for Fortis




    allegationsBidsBrian W TempestEast Bridge Capital Master FundFortisFortis HealthcareHarpal SinghIHH HealthcareinvestigationJupiter India FundNational Westminster BankRadiant Life CareSabina VaisohaSEBITejinder S Shergill
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok